| 30.11 0.09 (0.3%) | 05-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 36.37 | 1-year : | 42.48 |
| Resists | First : | 31.13 | Second : | 36.37 |
| Pivot price | 29.25 |
|||
| Supports | First : | 27.96 | Second : | 26 |
| MAs | MA(5) : | 30.12 |
MA(20) : | 28.9 |
| MA(100) : | 27.03 |
MA(250) : | 23.66 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 75.5 |
D(3) : | 74.9  |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 31.13 | Low : | 14.58 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PHVS ] has closed below upper band by 26.4%. Bollinger Bands are 5.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 30.47 - 30.62 | 30.62 - 30.75 |
| Low: | 28.89 - 29.06 | 29.06 - 29.2 |
| Close: | 29.85 - 30.12 | 30.12 - 30.35 |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Tue, 05 May 2026
Pharvaris Insider Sold Shares Worth $427,419, According to a Recent SEC Filing - marketscreener.com
Tue, 05 May 2026
Pharvaris (PHVS) CMO exercises $2.59 options, sells 14,166 shares under 10b5-1 plan - Stock Titan
Mon, 04 May 2026
Pharvaris N.v. Insider Sold Shares Worth $996,545, According to a Recent SEC Filing - Moomoo
Mon, 04 May 2026
Pharvaris N.v. Insider Sold Shares Worth $996,545, According to a Recent SEC Filing - marketscreener.com
Sat, 02 May 2026
Should New Deucrictibant Data on Dual HAE Use Require Action From Pharvaris (PHVS) Investors? - Sahm
Fri, 01 May 2026
Director at Pharvaris (NASDAQ: PHVS) trims stake via preset 10b5-1 sales - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 90.6 (%) |
| Shares Short | 1,130 (K) |
| Shares Short P.Month | 740 (K) |
| EPS | -3.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35.9 % |
| Return on Equity (ttm) | -65.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -137 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -8.66 |
| PEG Ratio | 0 |
| Price to Book value | 6.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|